In October 2025, the pan-Canadian Pharmaceutical Alliance (pCPA) and the Government of Ontario  announced new pathways to accelerate the funding of new drugs for Canadians. Canada currently ranks last among G7 countries in providing patients with timely access to innovative drugs. The pCPA has proposed two new expedited negotiation pathways, one for high-impact cancer drugs and another for non-complex negotiations. In tandem, the Government of Ontario announced a pilot program to fast-track funding for breakthrough cancer drugs.

Read the full publication